This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sowell, M. O. Articles by Dananberg, J. Search for Related Content PubMed PubMed Citation Articles by Sowell, M. O. Articles by Dananberg, J.

Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo

Eli Lilly \|[amp ]\| Co. (M.O.S., N.M., P.C., A.B., C.M.B., J.D.), Indianapolis, Indiana 46285; and Indiana University School of Medicine (S.S., H.O.S.), Indianapolis, Indiana 46202

Address all correspondence and requests for reprints to: Dr. Margaret O. Sowell, Lilly Research Laboratories, Eli Lilly \|[amp ]\| Co., Lilly Corporate Center, Drop Code 1758, Indianapolis, Indiana 46285. E-mail: . sowell_margaret_o{at}lilly.com

Abstract

The goal of this study was to evaluate the effect of olanzapine or risperidone treatment on ß-cell function in healthy volunteers. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d; n = 17), risperidone (4 mg/d; n = 13), or placebo (n = 18) for 15–17 d. Insulin secretion was quantitatively assessed at baseline and the end of the study period using the hyperglycemic clamp.

Weight increased significantly (P < 0.01) in the olanzapine (2.8 ± 1.7 kg) and risperidone (3.1 ± 2.1 kg) treatment groups. An increase (25%) in the insulin response to hyperglycemia and a decrease (18%) in the insulin sensitivity index were observed after treatment with olanzapine and risperidone. The change in insulin response was correlated (r = 0.5576; P = 0.019) with a change in body mass index. When the impact of weight change was accounted for by multivariate regression analyses, no significant change in insulin response or insulin sensitivity was detected after treatment with olanzapine or risperidone.

We found no evidence that treatment of healthy volunteers with olanzapine or risperidone decreased the insulin secretory response to a prolonged hyperglycemic challenge. The results of this study do not support the hypothesis that olanzapine or risperidone directly impair pancreatic ß-cell function.

This article has been cited by other articles:

				T. A. Hardy, A. L. Meyers, J. Yu, S. S. Shankar, H. O. Steinberg, and N. K. Porksen Acute Insulin Response and {beta}-Cell Compensation in Normal Subjects Treated With Olanzapine or Risperidone for 2 Weeks: Response to Jindal Diabetes Care, July 1, 2007; 30(7): e70 - e70. [Full Text] [PDF]

				A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia J Psychopharmacol, June 1, 2007; 21(4): 357 - 373. [Abstract] [PDF]

				T. A. Hardy, A. L. Meyers, J. Yu, S. S. Shankar, H. O. Steinberg, and N. K. Porksen Acute Insulin Response and {beta}-Cell Compensation in Normal Subjects Treated With Olanzapine or Risperidone for 2 Weeks Diabetes Care, January 1, 2007; 30(1): 157 - 158. [Full Text] [PDF]

				D. J. Klein, E. M. Cottingham, M. Sorter, B. A. Barton, and J. A. Morrison A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents Am J Psychiatry, December 1, 2006; 163(12): 2072 - 2079. [Abstract] [Full Text] [PDF]

				R. I. Holt Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 199 - 204. [Abstract] [PDF]

				B. Rubi, S. Ljubicic, S. Pournourmohammadi, S. Carobbio, M. Armanet, C. Bartley, and P. Maechler Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion J. Biol. Chem., November 4, 2005; 280(44): 36824 - 36832. [Abstract] [Full Text] [PDF]

				V. J. Fedorowicz and E. Fombonne Metabolic side effects of atypical antipsychotics in children: a literature review J Psychopharmacol, September 1, 2005; 19(5): 533 - 550. [Abstract] [PDF]

				D. E. Johnson, H. Yamazaki, K. M. Ward, A. W. Schmidt, W. S. Lebel, J. L. Treadway, E. M. Gibbs, W. S. Zawalich, and H. Rollema Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia Diabetes, May 1, 2005; 54(5): 1552 - 1558. [Abstract] [Full Text] [PDF]

				M. Ader, S. P. Kim, K. J. Catalano, V. Ionut, K. Hucking, J. M. Richey, M. Kabir, and R. N. Bergman Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in Dogs Diabetes, March 1, 2005; 54(3): 862 - 871. [Abstract] [Full Text] [PDF]

				K. A. Graham, D. O. Perkins, L. J. Edwards, R. C. Barrier Jr., J. A. Lieberman, and J. B. Harp Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis Am J Psychiatry, January 1, 2005; 162(1): 118 - 123. [Abstract] [Full Text] [PDF]

				D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al. Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis Arch Gen Psychiatry, January 1, 2005; 62(1): 19 - 28. [Abstract] [Full Text] [PDF]

				R. I. G. Holt Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists The British Journal of Psychiatry, April 1, 2004; 184(47): s55 - s63. [Abstract] [Full Text] [PDF]

				P. Cavazzoni, N. Mukhopadhyay, C. Carlson, A. Breier, and J. Buse Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications The British Journal of Psychiatry, April 1, 2004; 184(47): s94 - s101. [Abstract] [Full Text] [PDF]

				M. Sowell, N. Mukhopadhyay, P. Cavazzoni, C. Carlson, S. Mudaliar, S. Chinnapongse, A. Ray, T. Davis, A. Breier, R. R. Henry, et al. Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5875 - 5880. [Abstract] [Full Text] [PDF]

				L. L Citrome and A. B Jaffe Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus Ann. Pharmacother., December 1, 2003; 37(12): 1849 - 1857. [Abstract] [Full Text] [PDF]